Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
Stage set for access to Hepatitis C treatment in Malaysia
Community group taking actions to enable greater access for generic HCV treatment
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Updated WHO screening, care and treatment of persons with hepatitis C infection_ April 2016.
2018 IAS Brief Document Ending an Epidemic – Prioritizing People Who Inject Drugs in HCV elimination Efforts.
Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C